The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
Open accessAbstract
BACKGROUND: Cancers with a defective DNA mismatch repair (dMMR) system contain thousands of mutations most frequently located in monomorphic microsatellites and are thereby defined as having microsatellite instability (MSI). Therefore, MSI is a marker of dMMR. MSI/dMMR can be identified using immunohistochemistry to detect loss of MMR proteins and/or molecular tests to show microsatellite alterations. Together with tumour mutational burden (TMB) and PD-1/PD-L1 expression, it plays a role as a predictive biomarker for immunotherapy. METHODS: To define best practices to implement the detection of dMMR tumours in clinical practice, the ESMO Translational Research and Precision Medicine Working Group launched a collaborative project, based on a systematic review-approach, to generate consensus recommendations on the: (i) definitions related to the concept of MSI/dMMR; (ii) methods of MSI/dMMR testing and (iii) relationships between MSI, TMB and PD-1/PD-L1 expression. RESULTS: The MSI-related definitions, for which a consensus frame-work was used to establish definitions, included: 'microsatellites', 'MSI', 'DNA mismatch repair' and 'features of MSI tumour'. This consensus also provides recommendations on MSI testing; immunohistochemistry for the mismatch repair proteins MLH1, MSH2, MSH6 and PMS2 represents the first action to assess MSI/dMMR (consensus with strong agreement); the second method of MSI/dMMR testing is represented by polymerase chain reaction (PCR)-based assessment of microsatellite alterations using five microsatellite markers including at least BAT-25 and BAT-26 (strong agreement). Next-generation sequencing, coupling MSI and TMB analysis, may represent a decisive tool for selecting patients for immunotherapy, for common or rare cancers not belonging to the spectrum of Lynch syndrome (very strong agreement). The relationships between MSI, TMB and PD-1/PD-L1 expression are complex, and differ according to tumour types. CONCLUSIONS: This ESMO initiative is a response to the urgent questions raised by the growing success of immunotherapy and provides also important insights on the relationships between MSI, TMB and PD-1/PD-L1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · cited 3×
“For example, the panel with dinucleotides is being used in the ongoing phase II trials NCT03435107 and NCT03150706 (https://www.clinicaltrials. gov, last accessed 28 September 2018), whereas the panel with five poly-A repeats has been used in published trials Keynote-016 and Keynote-059 [7, 43].”
MethodMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 2×
“Another one hand-searched paper, investigating MSI status in more than 10 000 cancer patients, was selected to complete this subanalysis [6].”
BackgroundMethodComprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519 · cited 1×
“Notably, an estimation of TMB can also be made with targeted panels, avoiding the costs of whole-exome or of whole-genome sequencing [99, 100].”
BackgroundUmar, A., Boland, C. R., Terdiman, J. P., Syngal, S., Chapelle, A. D. L., Ruschoff, J., Fishel, R., Lindor, N. M., Burgart, L. J., Hamelin, R., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh034 · Cited by 3,183
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401 · cited 1×
“have applied NGS to the study of circulating tumour DNA during anti-PD-1 therapy, demonstrating that it might represent a valuable tool to assess tumour response in patients treated with immune checkpoint inhibitors [104, 105].”
MethodSelf-citationComprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Cristescu, R., Lee, J., Nebozhyn, M., Kim, K.-M., Ting, J. C., Wong, S. S., Liu, J., Yue, Y. G., Wang, J., Yu, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3850 · Cited by 2,223
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0013 · Cited by 1,784
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2644 · Cited by 1,592
Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Cederquist, L., Chan, E., Chen, Y.-J., Cooper, H. S., Deming, D., Engstrom, P. F., Enzinger, P. C., Fichera, A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0036 · Cited by 1,330
Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211
Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N. D., Kanchi, K. L., Maher, C. A., Fulton, R., Fulton, L., Wallis, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.024 · Cited by 1,146
Rodriguez-Bigas, M. A., Boland, C. R., Hamilton, S. R., Henson, D. E., Srivastava, S., Jass, J. R., Khan, P. M., Lynch, H., Smyrk, T., Perucho, M., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.23.1758 · Cited by 1,137
Hellmann, M. D., Nathanson, T., Rizvi, H., Creelan, B. C., Sanchez-Vega, F., Ahuja, A., Ni, A., Novik, J. B., Mangarin, L. M. B., Abu-Akeel, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.018 · Cited by 1,095 · cited 1×
“1%), but there is a very high percentage of PD-L1 positive cases (75% of cases, using as total the number of cases with TMB-high and/ or MSI and/or PD-L1 positive), although in NSCLC PD-L1 and TMB-high have been demonstrated to be independent [98].”
BackgroundClassification and characterization of microsatellite instability across 18 cancer types
Hause, R. J., Pritchard, C. C., Shendure, J., & Salipante, S. J. (2016) · Nature Medicine · doi:10.1038/nm.4191 · Cited by 991
Luchini, C., Stubbs, B., Solmi, M., & Veronese, N. (2017) · World Journal of Meta-Analysis · doi:10.13105/wjma.v5.i4.80 · Cited by 977
Self-citationMicrosatellite Instability as a Biomarker for PD-1 Blockade
Dudley, J. C., Lin, M.-T., Le, D. T., & Eshleman, J. R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1678 · Cited by 931
MSIsensor: microsatellite instability detection using paired tumor-normal sequence data
Niu, B., Ye, K., Zhang, Q., Lu, C., Xie, M., McLellan, M. D., Wendl, M. C., & Ding, L. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt755 · Cited by 832
Ligtenberg, M. J. L., Kuiper, R. P., Chan, T. L., Goossens, M., Hebeda, K. M., Voorendt, M., Lee, T. Y. H., Bodmer, D., Hoenselaar, E., Hendriks-Cornelissen, S. J. B., et al. (2009) · Nature Genetics · doi:10.1038/ng.283 · Cited by 818
Self-citationHowitt, B. E., Shukla, S. A., Sholl, L. M., Ritterhouse, L. L., Watkins, J. C., Rodig, S., Stover, E., Strickland, K. C., D’Andrea, A. D., Wu, C. J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2151 · Cited by 684
Shia, J. (2008) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.080031 · Cited by 643
Suraweera, N., Duval, A., Reperant, M., Vaury, C., Furlan, D., Leroy, K., Seruca, R., Iacopetta, B., & Hamelin, R. (2002) · Gastroenterology · doi:10.1053/gast.2002.37070 · Cited by 620
Baretti, M., & Le, D. T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.004 · Cited by 556
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.034 · Cited by 552
Duffy, M. J., van Dalen, A., Haglund, C., Hansson, L., Holinski-Feder, E., Klapdor, R., Lamerz, R., Peltomaki, P., Sturgeon, C., & Topolcan, O. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.03.021 · Cited by 506
Vanderwalde, A., Spetzler, D., Xiao, N., Gatalica, Z., & Marshall, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1372 · Cited by 458
Hodges, T. R., Ott, M., Xiu, J., Gatalica, Z., Swensen, J., Zhou, S., Huse, J. T., de Groot, J., Li, S., Overwijk, W. W., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox026 · Cited by 404
Microsatellite Instability Detection by Next Generation Sequencing
Salipante, S. J., Scroggins, S. M., Hampel, H. L., Turner, E. H., & Pritchard, C. C. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.223677 · Cited by 399
The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes
Kim, T.-M., Laird, P. W., & Park, P. J. (2013) · Cell · doi:10.1016/j.cell.2013.10.015 · Cited by 380
Middha, S., Zhang, L., Nafa, K., Jayakumaran, G., Wong, D., Kim, H. R., Sadowska, J., Berger, M. F., Delair, D. F., Shia, J., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00084 · Cited by 377
Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
Janjigian, Y. Y., Sanchez-Vega, F., Jonsson, P., Chatila, W. K., Hechtman, J. F., Ku, G. Y., Riches, J. C., Tuvy, Y., Kundra, R., Bouvier, N., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0787 · Cited by 375
Intratumoral immunotherapy: using the tumor as the remedy
Marabelle, A., Tselikas, L., de Baere, T., & Houot, R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx683 · Cited by 375
Stoffel, E. M., Mangu, P. B., Gruber, S. B., Hamilton, S. R., Kalady, M. F., Lau, M. W. Y., Lu, K. H., Roach, N., & Limburg, P. J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1322 · Cited by 373
Duffy, M. J., Lamerz, R., Haglund, C., Nicolini, A., Kalousová, M., Holubec, L., & Sturgeon, C. (2014) · International Journal of Cancer · doi:10.1002/ijc.28384 · Cited by 360
Postreplicative Mismatch Repair
Jiricny, J. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012633 · Cited by 344
Practical guidance for mismatch repair-deficiency testing in endometrial cancer
Stelloo, E., Jansen, A. M. L., Osse, E. M., Nout, R. A., Creutzberg, C. L., Ruano, D., Church, D. N., Morreau, H., Smit, V. T. H. B. M., van Wezel, T., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw542 · Cited by 342
Self-citationCabel, L., Riva, F., Servois, V., Livartowski, A., Daniel, C., Rampanou, A., Lantz, O., Romano, E., Milder, M., Buecher, B., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx212 · Cited by 315
Polom, K., Marano, L., Marrelli, D., De Luca, R., Roviello, G., Savelli, V, Tan, P., & Roviello, F. (2018) · Journal of British Surgery · doi:10.1002/bjs.10663 · Cited by 292
Engel, K. B., & Moore, H. M. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0702-rair.1 · Cited by 257
Cohen, R., Hain, E., Buhard, O., Guilloux, A., Bardier, A., Kaci, R., Bertheau, P., Renaud, F., Bibeau, F., Fléjou, J.-F., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4942 · Cited by 248
Self-citationGoodman, A. M., Piccioni, D., Kato, S., Boichard, A., Wang, H.-Y., Frampton, G., Lippman, S. M., Connelly, C., Fabrizio, D., Miller, V., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1701 · Cited by 247
Salem, M. E., Puccini, A., Grothey, A., Raghavan, D., Goldberg, R. M., Xiu, J., Korn, W. M., Weinberg, B. A., Hwang, J. J., Shields, A. F., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0735 · Cited by 217
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
Panda, A., Mehnert, J. M., Hirshfield, K. M., Riedlinger, G., Damare, S., Saunders, T., Kane, M., Sokol, L., Stein, M. N., Poplin, E., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx213 · Cited by 208
Gong, J., Wang, C., Lee, P. P., Chu, P., & Fakih, M. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0016 · Cited by 207
Vasen, H. F. A., Ghorbanoghli, Z., Bourdeaut, F., Cabaret, O., Caron, O., Duval, A., Entz-Werle, N., Goldberg, Y., Ilencikova, D., Kratz, C. P., et al. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2013-102238 · Cited by 206
The therapeutic significance of mutational signatures from DNA repair deficiency in cancer
Ma, J., Setton, J., Lee, N. Y., Riaz, N., & Powell, S. N. (2018) · Nature Communications · doi:10.1038/s41467-018-05228-y · Cited by 195
Self-citationAssociation of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer
Li, X., Pasche, B., Zhang, W., & Chen, K. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2805 · Cited by 195
Deficient mismatch repair: Read all about it (Review)
RICHMAN, S. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3119 · Cited by 186
Salem, M. E., Puccini, A., Xiu, J., Raghavan, D., Lenz, H.-J., Korn, W. M., Shields, A. F., Philip, P. A., Marshall, J. L., & Goldberg, R. M. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0143 · Cited by 185
Testing guidelines for hereditary non-polyposis colorectal cancer
Umar, A., Risinger, J. I., Hawk, E. T., & Barrett, J. C. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1278 · Cited by 184
Pattern recognition receptors: immune targets to enhance cancer immunotherapy
Shekarian, T., Valsesia-Wittmann, S., Brody, J., Michallet, M. C., Depil, S., Caux, C., & Marabelle, A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx179 · Cited by 181
An Optimized Pentaplex PCR for Detecting DNA Mismatch Repair-Deficient Colorectal Cancers
Goel, A., Nagasaka, T., Hamelin, R., & Boland, C. R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009393 · Cited by 179
Heald, B., Plesec, T., Liu, X., Pai, R., Patil, D., Moline, J., Sharp, R. R., Burke, C. A., Kalady, M. F., Church, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.1674 · Cited by 178
Constitutional mismatch repair-deficiency syndrome
Wimmer, K., & Kratz, C. P. (2010) · Haematologica · doi:10.3324/haematol.2009.021626 · Cited by 172
Nowak, J. A., Yurgelun, M. B. B., Bruce, J. L., Rojas‐Rudilla, V., Hall, D. L., Shivdasani, P., Garcia, E. P., Agoston, A. T., Srivastava, A., Ogino, S., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.07.010 · Cited by 172
Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines
Balmaña, J., Balaguer, F., Cervantes, A., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt209 · Cited by 165
Report From the Jerusalem Workshop on Lynch Syndrome-Hereditary Nonpolyposis Colorectal Cancer
Boland, C. R., & Shike, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.024 · Cited by 162
Pal, T., Permuth‐Wey, J., Kumar, A., & Sellers, T. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1387 · Cited by 150
Díaz-Padilla, I., Romero-Laorden, N., Amir, E., Matías‐Guiu, X., Vilar, E., Muggia, F. M., & García-Donás, J. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.03.002 · Cited by 142
Entius, M. M., Keller, J. J., Drillenburg, P., Kuypers, K. C., Giardiello, F. M., & Offerhaus, G. J. A. (2000) · PubMed · Cited by 137
Luchini, C., Pea, A., Lionheart, G., Mafficini, A., Nottegar, A., Veronese, N., Chianchiano, P. E., Brosens, L. A. A., Noë, M., Offerhaus, G. J. A., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4941 · Cited by 134
Self-citationMurphy, M., & Wentzensen, N. (2010) · International Journal of Cancer · doi:10.1002/ijc.25835 · Cited by 127
Gatalica, Z., Xiu, J., Swensen, J. J., & Vranić, S. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.021 · Cited by 127
The clinical importance and prognostic implications of microsatellite instability in sporadic cancer
Lawes, D., SenGupta, S. B., & Boulos, P. B. (2003) · European Journal of Surgical Oncology · doi:10.1053/ejso.2002.1399 · Cited by 124
An Update on Immunotherapy for Solid Tumors: A Review
Pham, T. D., Roth, S., Kong, J. C. H., Guerra, G., Narasimhan, V., Pereira, L. A., Desai, J., Heriot, A. G., & Ramsay, R. G. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6658-4 · Cited by 108
A meta-analysis of MSI frequency and race in colorectal cancer
Ashktorab, H., Ahuja, S., Kannan, L., Llor, X., Ellis, N. A., Xicola, R. M., Laiyemo, A. O., Carethers, J. M., Brim, H., & Nouraie, M. S. (2016) · Oncotarget · doi:10.18632/oncotarget.8945 · Cited by 99
Luchini, C., Cros, J. F., Pea, A., Pilati, C., Veronese, N., Rusev, B. C., Capelli, P., Mafficini, A., Nottegar, A., Brosens, L. A. A., et al. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.07.006 · Cited by 89
Self-citationBellone, S., Bignotti, E., Lonardi, S., Ferrari, F., Centritto, F., Masserdotti, A., Pettinella, F., Black, J., Menderes, G., Altwerger, G. H., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.11.023 · Cited by 84
Pearlman, R., Markow, M., Knight, D. A., Chen, W., Arnold, C. A., Pritchard, C. C., Hampel, H., & Frankel, W. L. (2018) · Modern Pathology · doi:10.1038/s41379-018-0058-y · Cited by 83
Implications of mismatch repair-deficient status on management of early stage colorectal cancer.
Kawakami, H., Zaanan, A., & Sinicrope, F. A. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2015.065 · Cited by 82
Bernardi, M. ‐., Ngan, S. Y., Michael, M., Lynch, A. C., Heriot, A. G., Ramsay, R. G., & Phillips, W. A. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00292-2 · Cited by 80
Boichard, A., Tsigelny, I. F., & Kurzrock, R. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1284719 · Cited by 78
Barrett, M. T., Lenkiewicz, E., Malasi, S., Basu, A., Yearley, J. H., Annamalai, L., McCullough, A. E., Kosiorek, H., Narang, P., Sayres, M. A. W., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1004-0 · Cited by 77
Qin, Y. W., Ekmekçioglu, S., Forget, M., Székvölgyi, L., Hwu, P., Grimm, E. A., Jazaeri, A. A., & Roszik, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00689 · Cited by 75
Kawazoe, A., Shitara, K., Kuboki, Y., Bando, H., Kojima, T., Yoshino, T., Ohtsu, A., Ochiai, A., Togashi, Y., Nishikawa, H., et al. (2018) · Gastric Cancer · doi:10.1007/s10120-018-0843-9 · Cited by 65
Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE-Mutant Uterine Carcinosarcoma
Bhangoo, M. S., Boasberg, P. D., Mehta, P., Elvin, J. A., Ali, S. M., Wu, W., & Klempner, S. J. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0342 · Cited by 58
Gastric Carcinomas With Lymphoid Stroma: An Evaluation of the Histopathologic and Molecular Features
Hissong, E. M., Ramrattan, G., Zhang, P., Zhou, X. K., Young, G. Q., Klimstra, D. S., Shia, J., Fernandes, H., & Yantiss, R. K. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001018 · Cited by 53
Hissong, E. M., Crowe, E. P., Yantiss, R. K., & Chen, Y. (2018) · Modern Pathology · doi:10.1038/s41379-018-0094-7 · Cited by 53
Hatakeyama, K., Nagashima, T., Urakami, K., Ohshima, K., Serizawa, M., Ohnami, S., Shimoda, Y., Ohnami, S., Maruyama, K., Naruoka, A., et al. (2018) · Biomedical Research · doi:10.2220/biomedres.39.159 · Cited by 49
Nakagomi, T., Goto, T., Hirotsu, Y., Shikata, D., Yokoyama, Y., Higuchi, R., Amemiya, K., Okimoto, K., Oyama, T., Mochizuki, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24365 · Cited by 48
PD-L1 testing, fit for routine evaluation? From a pathologist’s point of view
Hutarew, G. (2016) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-016-0292-2 · Cited by 45
Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer
Jenkins, R. W., Thummalapalli, R., Carter, J., Cañadas, I., & Barbie, D. A. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-060116-022926 · Cited by 43
Colorectal Carcinomas With Isolated Loss of PMS2 Staining by Immunohistochemistry
Alpert, L., Pai, R. K., Srivastava, A., McKinnon, W. C., Wilcox, R. L., Yantiss, R. K., Arcega, R. S., Wang, H. L., Robert, M. E., Liu, X., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0156-oa · Cited by 40
Gkekas, I., Novotný, J. P., Pecen, L., Strigård, K., Palmqvist, R., & Gunnarsson, U. (2017) · Anticancer Research · doi:10.21873/anticanres.12113 · Cited by 35
Weinberg, B. A., Xiu, J., Hwang, J. J., Shields, A. F., Salem, M. E., & Marshall, J. L. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0034 · Cited by 29
Alfonso, P. G., Salazar, R., García‐Foncillas, J., Musulén, E., García‐Carbonero, R., Payá, A., Pérez‐Segura, P., y Cajal, S. R., & Navarro, S. (2012) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0856-5 · Cited by 27
Villaruz, L. C., Hunter, K. A., Kurland, B. F., Abberbock, S. R., Herbst, C., & Đačić, S. (2018) · Histopathology · doi:10.1111/his.13729 · Cited by 24
Cancer predisposition syndromes: lessons for truly precision medicine
Glaire, M. A., Brown, M., Church, D. N., & Tomlinson, I. P. M. (2016) · The Journal of Pathology · doi:10.1002/path.4842 · Cited by 21
Inaguma, S., Lasota, J. P., Felisiak-Gołąbek, A., Kowalik, A., Wang, Z., Zięba, S., Kalisz, J., Ikeda, H., & Miettinen, M. (2017) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.81 · Cited by 21
Ponti, G., Pellacani, G., Ruini, C., Percesepe, A., Longo, C., Mandel, V. D., Crucianelli, F., Gorelli, G., & Tomasi, A. (2014) · Familial Cancer · doi:10.1007/s10689-014-9733-4 · Cited by 19
Somasundaram, A., & Burns, T. F. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s105678 · Cited by 15
Strategies for clinical implementation of screening for hereditary cancer syndromes
Heald, B., Marquard, J., & Funchain, P. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.08.008 · Cited by 12
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer
The Singapore Cancer Network (SCAN) Colorectal Cancer Systemic Therapy Workgroup (2015) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v44n10p379 · Cited by 7
Lynch syndrome (HNPCC) and microsatellite instability analysis guidelines
Umar, A. (2006) · Cancer Biomarkers · doi:10.3233/cbm-2006-21-201 · Cited by 4
Guidelines for microsatellite PCR genotyping from picogram amounts of DNA.
Weissensteiner, T. (1997) · Europe PMC (PubMed Central) · Cited by 1
Cited by
Immune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353
“Microsatellite unstable tumours have been categorized into two phenotypes namely MSI-low (MSI-L) and MSI-high (MSI-H) that the latter enhanced significantly the neoantigen load, leading to activating lymphocyte, thereby rendering tumour cells sensitive to ICIs [116].”
BackgroundDostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Mirza, M. R., Chase, D. M., Slomovitz, B. M., dePont Christensen, R., Novák, Z., Black, D., Gilbert, L., Sharma, S., Valabrega, G., Landrum, L. M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2216334 · Cited by 862
Turning cold tumors hot: from molecular mechanisms to clinical applications
Zhang, J., Huang, D., Saw, P. E., & Song, E. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.04.010 · Cited by 534
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 535
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Cheng, A.-L., Hsu, C., Chan, S. L., Choo, S.-P., & Kudo, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.025 · Cited by 528
Metadata
- Authors
- Luchini, C., Bibeau, F., Ligtenberg, M. J. L., Singh, N., Nottegar, A., Bosse, T., Miller, R., Riaz, N., Douillard, J.-Y., Andre, F., & Scarpa, A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 30
- Issue
- 8
- Pages
- 1232-1243
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2944675676
- Cited by
- 1,041
- References
- 102
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.